EndoSpan Overview
Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Endospan helps make the treatment of aneurysms, dissections, and aortic lesions simpler and less invasive, making it a suitable choice for patients with limited treatment options. Endospan's HORIZON system can be used in a single-sided approach, generally shortening and simplifying EVAR procedures. It is especially useful for patients for whom a two-sided approach is physically impossible because of occlusions, natural anatomical contraindications, or other pathologies arising from prior surgical intervention. The company's NEXUS is an aortic stent graft system whose modular approach offers a minimally invasive endovascular solution for patients diagnosed with an aneurysm in the ascending aorta or the aortic arch. In March 2019, Endospan announced that it received the CE Mark for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.
Cumulative Funding Raised Over Time ($)
—Jan 2013
$25.0MJul 2024
$35.0MOct 2015
$50.0MSep 2019
$60.0MSep 2019
Latest News
growth-positive
ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH
Endospan Ltd, an Israeli-based company, has announced an agreement with Artivion, Inc for additional loans of up to $25 million to support the FDA approval process for its NEXUS Stent Graft System. This partnership aims to advance the IDE study with the FDA, offering minimally invasive solutions for patients with aortic arch disease. The NEXUS system, already CE-marked in Europe, is the first approved branched endovascular system for treating aortic arch disease, addressing a significant market opportunity. The TRIOMPHE IDE Study is currently enrolling patients to evaluate the safety and effectiveness of NEXUS. The collaboration with Artivion is expected to enhance Endospans ability to provide innovative solutions for complex aortic conditions.
InvestmentPartners
Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System
Endospan Enrolls First Patient in the TRIOMPHE IDE Study
Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System
FDA Grants NEXUS™ Aortic Arch Stent Graft System Breakthrough Designation
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $20M |
| Last funding | $25M |
| Stage | B |
| Rounds | 5 |
| Investors | 5 |
Team Members
6
Employees: 51-200
Web & Social Links
| Website | www.endospan.com |
| Careers | Careers page |
Locations
Maskit Street 4, Herzliyya, Israel
Photos & Videos
2 item(s)
EndoSpan Business
Business models
B2B
Product stage
Released
Employees
51-200
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
—Tags (7)
surgeonsvascularmedical-devicescardiovascularstentsurgerycardiologyGeographic Markets
EuropeEndoSpan Financials
$20M
Total funding
Undisclosed
Capital raised
$25M
Last funding
B
Funding stage
5
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
—Jan 2013
$25.0MJul 2024
$35.0MOct 2015
$50.0MSep 2019
$60.0MSep 2019
Private Equity Funding
Debt Financing
Jul 2024
$25M
Artivion (Lead)
Debt Financing
Sep 2019
$15M
CryoLife (Lead)
Undisclosed Round
Sep 2019
$10M
B Round
Oct 2015
$10M
Xizang Haisco Pharmaceutical Group, Accelmed, Sequoia Capital
A Round
Jan 2013
Undisclosed
Sequoia Capital
EndoSpan Lifecycle
Cumulative Funding Raised Over Time
—Jan 2013
$25.0MJul 2024
$35.0MOct 2015
$50.0MSep 2019
$60.0MSep 2019
All Events
Debt Financing
Jul 2024
$25M
Artivion (Lead)
Debt Financing
Sep 2019
$15M
CryoLife (Lead)
Undisclosed Round
Sep 2019
$10M
B Round
Oct 2015
$10M
Xizang Haisco Pharmaceutical Group, Accelmed, Sequoia Capital
A Round
Jan 2013
Undisclosed
Sequoia Capital
EndoSpan News
13 articles
growth-positive
ENDOSPAN RECEIVES ADDITIONAL $25M FROM ARTIVION FOR NEXUS FDA APPROVAL PATH
Endospan Ltd, an Israeli-based company, has announced an agreement with Artivion, Inc for additional loans of up to $25 million to support the FDA approval process for its NEXUS Stent Graft System. This partnership aims to advance the IDE study with the FDA, offering minimally invasive solutions for patients with aortic arch disease. The NEXUS system, already CE-marked in Europe, is the first approved branched endovascular system for treating aortic arch disease, addressing a significant market opportunity. The TRIOMPHE IDE Study is currently enrolling patients to evaluate the safety and effectiveness of NEXUS. The collaboration with Artivion is expected to enhance Endospans ability to provide innovative solutions for complex aortic conditions.
InvestmentPartners
Endospan Reports Landmark Publication on the Initial Experience With the NEXUS™ Aortic Arch Stent Graft System
Endospan Enrolls First Patient in the TRIOMPHE IDE Study
Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System
FDA Grants NEXUS™ Aortic Arch Stent Graft System Breakthrough Designation
growth-positive
CyroLife Signs Option to Acquire EndoSpan for up to $450 Million
CyroLife, a NYSE-listed cardiac and vascular surgery company, has signed a distribution agreement and option agreement to acquire Israeli stent graft company EndoSpan. CyroLife will pay $10 million for European distribution rights and provide up to $15 million in debt financing. The option agreement allows CyroLife to acquire EndoSpan for $350 million plus up to an additional $100 million depending on the systems commercial success.
PartnersInvestmentAcquisition
Endospan Enters Into Strategic Distribution Agreement With CryoLife
growth-positive
Endospan secures CE mark for Nexus stent graft system - Vascular News
Endospan has received CE mark approval for its Nexus stent graft system, which is used for branched endovascular repair in the aortic arch. The approval allows specialists in Europe to perform standardized minimally invasive repair of the aortic arch. The Nexus stent graft system provides a ready-to-treat technology solution that reduces the need for open surgery and lengthy hospitalization periods. The system is designed to achieve a durable effective repair while minimizing the risk of stroke and other cardiovascular complications. Endospan plans to expand the availability of Nexus with a limited market release across Europe and continue evaluating its long-term safety and effectiveness.
CustomersExpand
growth-positive
CE mark approval for Nexus aortic arch stent graft expected in Q1 2019 - Vascular News
The article discusses the mid-term results of an investigational clinical study of the Nexus aortic arch stent graft system by EndoSpan. The study showed a 100% success rate in access, deployment, and procedural survival in 25 patients. The device demonstrated an excellent safety profile with no aneurysm-related deaths. The company expects to receive CE approval for the device in the first quarter of 2019. Longer-term data is needed to further study the performance of the Nexus stent graft system.
Customers
growth-positive
Endospan Elects Jeff Elkins as a Director
Endospan, an Israel-based medical device company, has announced the appointment of Jeff Elkins to its board of directors. Elkins has significant experience in the medical device industry, having served as President and CEO of Veniti Inc. since July 2015. He has also held various operations and product-development management positions at Cordis and Cordis Endovascular Systems, and Haemonetics Corp. during its IPO. Endospan is currently developing NEXUS, the first off-the-shelf endovascular approach to treating aortic arch disease.
Management Changes
growth-positive
Endospan Receives CE Mark for HORIZON™ EVAR System Based on Robust Clinical and Pivotal Data to Treat Abdominal Aortic Aneurysm (AAA)
Endospan, a pioneer in off-the-shelf EndoVascular Aortic Repair (EVAR), has received CE marking for its HORIZON Stent Graft System to treat Abdominal Aortic Aneurysm (AAA). The company is looking forward to working with potential partners to commercialize the HORIZON system for AAA repair.
Partners
Endospan Appoints Kevin J. Mayberry as CEO
http://www.geektime.com/2015/10/22/chinese-pharma-company-pumps-10-million-in-israeli-heart-tech/
EndoSpan Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 59 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 6 classification IDs that could be used for matching.
EndoSpan Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 92/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 514172931 |
| Crunchbase | endospan |
| Phone | +97297884490 |
| Creator | Raz Zohar |
| Creator email | raz@platterz.ca |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-03T00:00:00.000Z |
| Created | 2014-09-07T00:00:00.000Z |